收藏切换
Reflections on the management of investigational products in the light of the revised Good Clinical Practice
收藏切换
Hui-zhen JIN1, Chen-mei MAO1, Ya-ru ZOU1, Ji-yin ZHOU2, *
Chinese Journal of New Drugs | 2026, 35(19) : 2055 - 2060
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(19): 2055-2060
Reflections on the management of investigational products in the light of the revised Good Clinical Practice
Full
Hui-zhen JIN1, Chen-mei MAO1, Ya-ru ZOU1, Ji-yin ZHOU2, *
Affiliations
  • 1 Children’s Hospital of Soochow University, Suzhou 215000, China
  • 2 Clinical Medical Research Center, the Second Affiliated Hospital, Army Medical University, Chongqing 400037, China
Published: 2026-10-15 doi: 10.20251/j.cnki.1003-3734.2026.19.005
Outline
收藏切换
Objective:

To explore the current application status, implementation considerations, and practical measures for a new model of delivering investigational drugs directly to trial participants (direct-to-subject, DTS) in the context of the revised Good Clinical Practice (GCP) and ICH E6 (R3), with the aim of providing a reference for optimizing its management quality.

Methods:

Through a literature review, this study compared regulatory policy differences, current implementation status, and common models for the direct-to-subject model between domestic and international settings, and analyze the key considerations for its implementation.

Results:

The direct-to-subject model has been adopted both domestically and internationally, but there is a lack of unified implementation guidelines. Its use may be considered when appropriate. Effective implementation can be ensured by strengthening the following aspects: clarification of responsibilities, ethical review, informed consent, risk assessment, qualification verification, training, information system development, risk management, privacy protection, and investigator oversight.

Conclusion:

The model aligns with the “patient-centered” philosophy but is still in its exploratory phase. When planning to adopt this approach, its feasibility should be fully demonstrated in the protocol, with enhanced emphasis on ethical review, training, and risk control, while clearly defining the responsibilities of all parties to safeguard participants’ rights and ensure data reliability.

investigational product management  /  direct-to-patient
金慧臻, 毛晨梅, 邹亚茹, 周吉银. 新版《药物临床试验质量管理规范》背景下试验用药品管理的思考. 中国新药杂志, 2026 , 35 (19) : 2055 -2060 . DOI: 10.20251/j.cnki.1003-3734.2026.19.005
Hui-zhen JIN, Chen-mei MAO, Ya-ru ZOU, Ji-yin ZHOU. Reflections on the management of investigational products in the light of the revised Good Clinical Practice[J]. Chinese Journal of New Drugs, 2026 , 35 (19) : 2055 -2060 . DOI: 10.20251/j.cnki.1003-3734.2026.19.005
Year 2026 volume 35 Issue 19
59
11
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.19.005
  • Receive Date:2026-07-13
  • Online Date:2026-10-29
  • Published:2026-10-15
Article Data
Affiliations
History
  • Received:2026-07-13
Funding
Affiliations
    1 Children’s Hospital of Soochow University, Suzhou 215000, China
    2 Clinical Medical Research Center, the Second Affiliated Hospital, Army Medical University, Chongqing 400037, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.19.005
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT